In 2004, the Journal of Clinical Oncology published a study about chemotherapy’s success rates when looking at how many cancer patients were still alive after 5 years. It states:
RESULTS: The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA.
CONCLUSION: As the 5-year relative survival rate for cancer in Australia is now over 60%, it is clear that cytotoxic chemotherapy only makes a minor contribution to cancer survival. To justify the continued funding and availability of drugs used in cytotoxic chemotherapy, a rigorous evaluation of the cost-effectiveness and impact on quality of life is urgently required.
You’d be hard pressed to find anything still being touted as your best shot at a cure with an average success rate of just over 2 percent, which chemotherapy has, if it wasn’t for the fact that big profits were driving the recommendation. For stage 4 cancers the rate is less than half of one percent.
Fundamentally, chemotherapy rarely works. Worse, some drug treatments also promote the spread of cancer. But somehow the rationale to avoid these agents because they might promote cancer does not apply when it comes to drugs.
A Cancer Journal for the Clinician article concludes by stating:
“Pending the publication of suitable trials, clinicians must be guided by existing data in the context of a fundamental principle of medicine, “Primum non nocere.” (First do no harm.) ”
And yet, conventional cancer treatments can in no way, shape or form ever be considered harmless.
“…as a chemist trained to interpret data, it is incomprehensible to me that physicians can ignore the clear evidence that chemotherapy does much, much more harm than good.”
— Alan C Nixon, PhD, former president of the American Chemical Society